This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
20 - 22 October, 2025
Presented in Japan Standard TimeThe Westin Miyako Kyoto

Delivered as a Hybrid Event

Dr. Richard Yu, PhD
CEO and Co-founder at Abalone Bio
Speaker

Profile

Richard Yu, co-founder, CEO, and board director, Ph.D., Mol. Biochemistry & Biophysics, 2000 Yale University Richard’s path to co-founding Abalone Bio started at UC Berkeley in Physics, Biophysics, and Computer Science. His first work was in protein secondary structure prediction with Teresa Head-Gordon at UC Berkeley/LBNL, which evolved into protein engineering and structural biology with Axel Brunger at Yale University. After receiving his PhD, he conducted postdoctoral research in systems and synthetic biology, studying information transmission in eukaryotic signal transduction systems with Roger Brent and Sydney Brenner at the Molecular Sciences Institute. Prior to Abalone Bio, he also co-founded and served as Chief Scientific Officer (CSO) at GPB, a cell engineering company focused on high-efficiency, low-cost biofuel production, and was Scientific and Operations Director at qb3@953 (now MBC Biolabs) in San Francisco.

Agenda Sessions

  • Discovery of GPCR Agonist Antibodies with Unique Activation Mechanisms Using the FAST Platform

    09:30